
CAS 1103522-45-7
:Aprocitentan
- Act-132577
Despropyl Macitentan (N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]sulfamide)
CAS:Compounds containing a pyrimidine ring, whether or not hydrogenated, or piperazine ring in the structure, nesoiFórmula:C16H14Br2N6O4SCor e Forma:Off-White SolidPeso molecular:543.9164Ref: IN-DA008TD9
1gA consultar1mg157,00€5mg161,00€10mg191,00€25mg240,00€50mg602,00€100mgA consultar250mgA consultarN-Despropyl Macitentan (Aprocitentan)
CAS:Fórmula:C16H14Br2N6O4SCor e Forma:White To Off-White SolidPeso molecular:546.20Aprocitentan
CAS:Aprocitentan (ACT-132577) is ETA and ETB antagonist .Fórmula:C16H14Br2N6O4SPureza:99.17%Cor e Forma:SolidPeso molecular:546.19Ref: TM-T7817
1mg58,00€5mg116,00€10mg170,00€25mg311,00€50mg439,00€100mg655,00€200mg887,00€1mL*10mM (DMSO)142,00€N-Despropyl-macitentan
CAS:Produto ControladoApplications N-Despropyl-macitentan, is an active metabolite which is part of a family of endothelin receptor antagonist that allows for treatment of pulmonary arterial hypertension (PAH)
References Atsmon, J., et al.: Clin. Pharmacokinet., 525, 685 (2013); Sidharta, P.N., et al.: Clin. Drug Invest. (2014)Fórmula:C16H14Br2N6O4SCor e Forma:NeatPeso molecular:546.19Aprocitentan
CAS:Apcitentan is a vasoactive drug that belongs to the group of endothelin receptor antagonists. It is used in the treatment of erectile dysfunction and pulmonary hypertension. Apcitentan inhibits the angiotensin system, which includes angiotensin-converting enzyme (ACE), angiotensin II type 1 receptor (AT1R) and angiotensin II type 2 receptor (AT2R). This inhibition increases the levels of endothelin and dopamine β-hydroxylase, thereby decreasing blood pressure. Apcitentan has been shown to increase glomerular filtration rate and reduce proteinuria in patients with chronic kidney disease. In vivo studies have shown that apcitentan is rapidly absorbed from the gastrointestinal tract, reaching peak concentrations within one hour. The pharmacodynamics of apcitentan are characterized by an inhibitory effect on pde5. Pharmacokinetic studies have found that apcitentan is metabolized by CYP
Fórmula:C16H14Br2N6O4SPureza:Min. 95%Peso molecular:546.19 g/mol









